Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11528 posts found.

Sprout sign

FDA approves ‘female viagra’

August 19, 2015 Research and Development, Sales and Marketing Addyi, FDA, HSDD, Sprout, Sprout Pharmaceuticals, flibanserin, hypoactive sexual desire disorder

The FDA has approved Sprout Pharmaceuticals’ Addyi, a controversial libido-enhancing drug for women that has been dubbed the ‘female viagra’. …
News
Chest x ray

Roche lung cancer therapy succeeds in mid-stage trial

August 17, 2015 Research and Development, Sales and Marketing Genentech, Roche, atezolizumab, lung cancer, non-small cell lung cancer

Roche’s biotech arm Genentech has scored positive results in a pivotal Phase II study of its investigational cancer immunotherapy atezolizumab. …
News
fda2outsideweb

FDA approves limited OxyContin use in children

August 17, 2015 Sales and Marketing FDA, OxyContin, Purdue, Purdue Pharma, oxycodone

The FDA has approved the limited use of the strong painkiller Oxycontin for children in the US aged between 11 …
News

Cost of diabetes treatment in England rises

August 12, 2015 Manufacturing and Production, Sales and Marketing HSCIC, NHS, diabetes, health and social care information centre, prescribing

As diabetes patients increase in numbers the cost of treating the disease in England has increased to more than £800 …
News
Kim Kardashian West Diclegis post

FDA warns drugmaker over Kim Kardashian West promo

August 12, 2015 Sales and Marketing Diclegis, Duchesnay, FDA, kim kardashian

Model and media personality Kim Kardashian West’s social media promotion of the morning sickness drug Diclegis has landed its producer …
News
Opdivo

Bristol-Myers Squibb launches Opdivo in the UK for lung cancer

August 12, 2015 Sales and Marketing BMS, Bristol-Myers Squibb, NSCLC, immunotherapy, lung cancer, non small cell lung cancer, non-small cell lung cancer, opdivo

The immuno-oncology drug Opdivo is available in the UK for people with lung cancer, after Bristol-Myers Squibb launched the drug …
News
Daiichi Sankyo

Daiichi scores another NICE nod for Lixiana

August 12, 2015 Sales and Marketing Daichii Sankyo, Daiichi, Lixiana, atrial fibrillation, edoxaban

NICE has recommended in draft guidance the anti-blood clotting drug Daiichi Sankyo’s Lixiana for preventing stroke and blood clots in …
News
George Freeman

UK medical innovation backed with £18m Biomedical Catalyst fund

August 10, 2015 Research and Development, Sales and Marketing

Life Sciences Minister George Freeman has announced an £18 million fund for the next generation of UK medical advances. Twelve …
News
R&D

Sanofi, Evotec and Apeiron partner on immuno-oncology

August 10, 2015 Research and Development, Sales and Marketing Apeiron, Cancer, Evotec, Sanofi, immuno-oncology, immunotherapy, tumours

Sanofi is partnering with biotech companies Evotec and Apeiron to develop new cancer immuno-oncology therapies.The companies say the potential new …
News
Nucynta (tapentadol)

Takeover hostilities resume between Depomed and Horizon

August 10, 2015 Sales and Marketing Depomed, horizon, hostile bid, nucynta, takeover, tapentadol

The bitter takeover row between Horizon and Depomed has escalated after Depomed dismissed its suitor’s latest advances, and warned it …
News

Pfizer and Flynn rapped for overcharging on anti-epilepsy drug

August 6, 2015 Manufacturing and Production, Sales and Marketing CMA, Drug pricing, Flynn Pharma, Pfizer, competitions markets authority, epilepsy, generics, phenytoin, pricing

Pharma firms Pfizer and Flynn Pharma have been accused by the UK’s competition watchdog of charging ‘excessive and unfair’ prices …
News
astrazeneca image

AstraZeneca buys rights to Heptares experimental cancer treatment

August 6, 2015 Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Cancer, HTL-1071, immuno-oncology

AstraZeneca has entered into a licensing agreement with Heptares for the global rights to the experimental cancer treatment HTL-1071. The …
News
NICE

NICE demands more evidence of Lynparza benefits

August 6, 2015 Sales and Marketing AstraZeneca, NICE, lynparza, ovarian cancer

AstraZeneca must provide a “robust estimate of the cost effectiveness” of its ovarian cancer treatment Lynparza, or risk being rejected …
News
pharma sales graph

Pharma industry worth more than $1 trillion – and growing

August 5, 2015 Sales and Marketing pharma sales, research and development

Global pharmaceutical sales are set to continue rising beyond the $1 trillion milestone reached in 2014, according to newly-released figures. …
News
Shire building

Shire goes public with rejected $30bn Baxalta bid

August 5, 2015 Research and Development, Sales and Marketing Baxalta, Shire, acquisitions, baxter, mergers, rare disease

Shire has confirmed that it made an all-share $30 billion offer to buy Baxalta last month, citing ’a strong strategic …
News
The Gateway to Local Adoption Series

Latest content

NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma

October 8, 2026

AstraZeneca’s Trixeo approved in EU for asthma

October 8, 2026

Amplio reports early human data for novel methotrexate approach in rheumatoid arthritis

October 7, 2026

Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial

October 6, 2026

ESTEVE CDMO adds $17.5m to Illinois expansion

October 6, 2026